Avalo Therapeutics
AVTX
26 hedge funds and large institutions have $16M invested in Avalo Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
5,978% more capital inflows, than outflows
Capital inflows: $11.9M | Capital outflows: $196K
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
37% more funds holding
Funds holding: 19 → 26 (+7)
10.18% more ownership
Funds ownership: 58.99% → 69.17% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VR Adviser
New York
|
+$3.28M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.97M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
+$1.56M |
| 4 |
Armistice Capital
New York
|
+$1.48M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$79K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 4 |
Meeder Asset Management
Dublin,
Ohio
|
-$4.73K |
| 5 |
Goldman Sachs
New York
|
-$3.15K |
AVTX Hedge Fund Activity: Q1 2023 in Review
26 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2023, worth a combined $16M — down 43% from $28M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVTX positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $3.28M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $95K sold.
- 26 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2023, up from 19 in Q4 2022.
- Funds reported $16M of Avalo Therapeutics stock for Q1 2023, down 43% quarter-over-quarter.
- 10 funds opened new Avalo Therapeutics positions in Q1 2023 and 3 closed out, a net change of +7 holders.
- The largest Avalo Therapeutics buyer in Q1 2023 was VR Adviser, an estimated $3.28M added.
- The largest Avalo Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $95K sold.
Based on aggregated 13F filings for Q1 2023.